StockNews.com Begins Coverage on DBV Technologies (NASDAQ:DBVT)

Stock analysts at StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Tuesday. The brokerage set a “hold” rating on the stock.

Other equities analysts also recently issued research reports about the company. JMP Securities reiterated a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research note on Tuesday, December 10th. HC Wainwright upped their target price on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Stock Performance

DBV Technologies stock opened at $3.30 on Tuesday. The firm has a market cap of $67.88 million, a price-to-earnings ratio of -0.73 and a beta of 0.64. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $10.70. The firm has a 50 day moving average price of $3.43 and a two-hundred day moving average price of $3.96.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.